Physician profile
Rao Meka
NPI 1275608853
$4,732.30
in general payments reported to CMS, 2019-2025
34 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $535 · 2021: $1,529 · 2022: $577 · 2023: $554 · 2024: $192 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.03 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $599.67 | 2020-2025 | Relistor, Trulance, Xifaxan |
| Pfizer INC. | $348.36 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $275.98 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $240.25 | 2019-2023 | Dificid |
| Amarin Pharma, INC. | $223.04 | 2019 | |
| Evoke Pharma, INC. | $179.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.73 | 2019-2025 | Entyvio, Eohilia |
| Redhill Biopharma INC. | $128.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $124.96 | 2019 | |
| Ardelyx, INC. | $119.20 | 2022-2024 | Ibsrela |
| Janssen Scientific Affairs, LLC | $116.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $88.52 | 2019-2020 | |
| Gilead Sciences, INC. | $85.65 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $73.60 | 2021-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $73.26 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $66.46 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $54.38 | 2021-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $53.43 | 2025 | Iqirvo |
| Qol Medical, LLC | $52.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.94 | 2020-2023 | Cyltezo |
| Glaxosmithkline, LLC. | $36.58 | 2019-2020 | |
| Janssen Biotech, INC. | $33.85 | 2019-2024 | Stelara, Tremfya |
| Boston Scientific Corporation | $30.70 | 2019 | |
| Braintree Laboratories, INC. | $28.82 | 2020-2021 | |
| Meridian Bioscience INC. | $26.75 | 2022 | |
| Dova Pharmaceuticals | $22.52 | 2020 | |
| Gebauer Company | $20.12 | 2022 | |
| Genzyme Corporation | $18.12 | 2023 | |
| Aimmune Therapeutics, INC. | $14.99 | 2025 | Zenpep |
| Amgen INC. | $11.70 | 2020 | |
| Vivus LLC | $11.11 | 2021 | |
| Intra-Sana Laboratories | $6.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rao Meka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.